A Multicenter Phase II Study of Capecitabine and Docetaxel for Previously Treated Pancreatic Cancer Patients 'CapTere'.

Trial Profile

A Multicenter Phase II Study of Capecitabine and Docetaxel for Previously Treated Pancreatic Cancer Patients 'CapTere'.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Capecitabine (Primary) ; Docetaxel (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms CapTere
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Sep 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 21 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top